To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Stem Cell Therapy market size was valued at USD 369.62 Million in 2024 and is poised to grow from USD 438.74 Million in 2025 to USD 1729.07 Million by 2033, growing at a CAGR of 18.7% in the forecast period (2026–2033).

    The global stem cell therapy market is extremely competitive worldwide, with major competitors spearheading research and growth. Global firms like Medipost Co. Ltd., Takeda Pharmaceuticals, and Smith & nephew plc have strong R&D pipelines and advanced stem cell therapies. They focus on clinical trials and subsequent launches of new products or strategic partnerships as a way of maintaining their competitive edge. Biotech companies are increasingly collaborating with each other, CROs, CDMOs and academic institutions in the market to fast track the development of novel therapeutics. BrainStorm Cell Therapeutics, for example, had recently in May 2025, signed an LOI with Minaris Advanced Therapies, a CDMO, to manufacture NurOwn, a stem cell-based therapy, for its upcoming Phase 3b ALS clinical trial in the U.S. 'Smith & Nephew plc (United Kingdom)', 'Medipost Co. Ltd. (South Korea)', 'JCR Pharmaceuticals Co., Ltd. (Japan)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Anterogen Co., Ltd. (South Korea)', 'Corestem, Inc. (South Korea)', 'Pharmicell Co., Ltd (South Korea)', 'NuVasive, Inc. (United States)', 'Holostem SRL (Italy)', 'Orthofix Medical Inc. (United States)', 'Stempeutics Research Pvt Ltd. (India)', 'Regrow Biosciences Pvt Ltd. (India)', 'Healios KK (Japan)', 'Mesoblast Ltd. (Australia)', 'BioRestorative Therapies, Inc. (United States)', 'Pluri Inc. (Israel)', 'BrainStorm Cell Inc (United States)', 'Ayrmid Limited (Gamida Cell) (United Kingdom)', 'Vertex Pharmaceuticals (ViaCyte, Inc.) (United States)', 'Kangstem Biotech Co., Ltd. (South Korea)'

    Financial assistance from governmental organizations and appropriate regulatory frameworks promotes a conducive atmosphere for stem cell therapy research and development. Increased research efforts and availability of funding for cell-based studies have generally arisen from the need for better and more creative treatment options for autoimmune, neurological, and cardiovascular diseases. In March 2025, the Government of Canada has invested $49.9 million in StemCell Technologies Canada Inc. to support a $222 million project for establishing two new biomanufacturing facilities in British Columbia.

    Companies Seek Specialized Talent Amidst Innovation in Therapeutics:

    The North America stem cell therapy market emerges as the most dominant stem cell therapy market in the world. The region's importance can be attributed to advanced healthcare infrastructure, high R&D investments, and the presence of established and prominent biotechnology firms in the region. Support from regulatory frameworks, national regulatory agencies’ approvals for stem cell therapies, and rising prevalence of chronic diseases also adds to market growth. The United States emerges as a hub for stem cell therapy in the region using these therapies across hospitals and specialty clinics.

    Feedback From Our Clients

    Global Stem Cell Therapy Market

    Report ID: SQMIG35H2162

    $5,300
    BUY NOW